Journal of Extracellular Vesicles

JEV considers research articles as well as review articles, short communications, technical notes, hypotheses, position papers, editorials, and letters to the editor. The journal has published the current consensus guidelines for the EV field, the Minimal Information for Studies of EVs (MISEV2023), building on previous guidelines released in 2018 and 2014 ("MISEV2018" and "MISEV2014"). ==Notable articles==

The journal has published numerous influential articles. These include position papers of ISEV as well as the periodically updated consensus guidelines for the EV field, which are based on expert opinion and crowdsourcing. Several key articles were summarized in an editorial in 2019 by the then-outgoing editors-in-chief. • The current consensus guidelines for the EV field, known as "MISEV2023", were prepared with input from more than 1050 co-authors. • A position paper on therapeutic applications of EVs was published in 2015. • A comprehensive review article on EVs was published in 2015 by María Yáñez-Mó, Pia Siljander, and colleagues. • Considerations for studies of RNA and EVs were recommended in 2017 following a Workshop in Utrecht, The Netherlands • During the COVID-19 pandemic, ISEV and the International Society for Gene and Cell Therapy released a statement on EV therapies for COVID-19. • The nomenclature of EVs was addressed in "Extracellular vesicles or exosomes? On primacy, precision, and popularity influencing a choice of nomenclature". ==History==

JEV was established in April 2012, soon after the founding of ISEV. The journal was published by Co-Action Publishing for more than four years. ==Abstracting and indexing==

The journal is abstracted and indexed in: According to the Journal Citation Reports, the journal has a 2022 impact factor of 16.0. ==References==